Examkin

Question

Difficulty: EasyMonitoring and Treatment Evaluation

A 5454-year-old woman is evaluated in the ambulatory care clinic and diagnosed with primary hypertension. Her blood pressure is 154/92 mmHg154/92\text{ mmHg}. She has no other chronic medical conditions and takes no daily medications. Baseline laboratory studies reveal a creatinine level of 0.9 mg/dL0.9\text{ mg/dL} and a potassium level of 4.1 mEq/L4.1\text{ mEq/L}. The physician initiates once-daily oral lisinopril. The patient is scheduled for a follow-up appointment.

Which of the following is the most appropriate next step in monitoring this patient's new pharmacotherapy?

  1. A
    Order 2424-hour ambulatory blood pressure monitoring before obtaining further laboratory tests
  2. B
    Perform a renal artery Doppler ultrasound to evaluate for secondary causes
  3. Obtain a basic metabolic panel to assess renal function and electrolytes in 22 to 44 weeksAnswer
  4. D
    Discontinue the medication if the follow-up creatinine level increases to 1.1 mg/dL1.1\text{ mg/dL}
  5. E
    Initiate concomitant spironolactone therapy to prevent medication-induced hypokalemia

Answer

Obtain a basic metabolic panel to assess renal function and electrolytes in 22 to 44 weeks
The correct option identifies the standard of care for monitoring patients newly started on ACE inhibitors. Because these medications alter intrarenal hemodynamics by dilating the efferent arteriole, they can cause an initial decrease in glomerular filtration rate, leading to an elevated creatinine level. Additionally, reduced aldosterone secretion increases the risk of hyperkalemia. Therefore, checking a basic metabolic panel within 22 to 44 weeks of initiation is essential to ensure patient safety.

Step-by-Step Solution

1
Identify the newly prescribed medication and its mechanism of action.
The patient was started on lisinopril, an ACE inhibitor, which blocks angiotensin II, leading to efferent arteriole vasodilation.
Understanding the drug's mechanism is required to predict its physiological effects on the kidneys and electrolyte balance.
2
Determine the expected physiological changes and potential adverse effects of the medication.
Efferent vasodilation causes a mild reduction in glomerular filtration rate (GFR) and reduced aldosterone secretion, which increases potassium retention.
Anticipating these changes guides the selection of the appropriate safety monitoring parameters.
3
Select the most appropriate monitoring timeframe and parameter based on standard guidelines.
A basic metabolic panel should be obtained in 22 to 44 weeks to check for acute kidney injury and hyperkalemia.
This time window allows the medication to reach a steady physiological effect while ensuring any dangerous electrolyte or renal shifts are caught early.

Key Concept

Monitoring for acute kidney injury and hyperkalemia 22 to 44 weeks after initiating ACE inhibitor therapy.
Estimated Time:1m 0s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic